Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1995 1
1997 1
2010 3
2011 3
2012 4
2013 1
2014 2
2015 1
2016 2
2017 2
2018 1
2019 2
2020 1
2021 4
2022 1
2023 4
2024 5
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. DiPeri TP, et al. Among authors: evans kw. Cancer Discov. 2024 May 1;14(5):828-845. doi: 10.1158/2159-8290.CD-23-0838. Cancer Discov. 2024. PMID: 38358339 Free PMC article. Clinical Trial.
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.
Meric-Bernstam F, Yuca E, Evans KW, Zhao M, Maejima T, Karibe T, Raso MG, Tang X, Zheng X, Rizvi YQ, Akcakanat A, Scott SM, Wang B, Byers LA, Tripathy D, Okajima D, Damodaran S. Meric-Bernstam F, et al. Among authors: evans kw. Clin Cancer Res. 2025 Feb 3;31(3):573-587. doi: 10.1158/1078-0432.CCR-24-1948. Clin Cancer Res. 2025. PMID: 39585341 Free PMC article.
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.
DiPeri TP, Evans KW, Scott S, Zheng X, Varadarajan K, Kwong LN, Kahle M, Tran Cao HS, Tzeng CW, Vu T, Kim S, Su F, Raso MG, Rizvi Y, Zhao M, Wang H, Lee SS, Yap TA, Rodon J, Javle M, Meric-Bernstam F. DiPeri TP, et al. Among authors: evans kw. Clin Cancer Res. 2025 Jan 17;31(2):387-402. doi: 10.1158/1078-0432.CCR-24-1233. Clin Cancer Res. 2025. PMID: 39513959 Free PMC article.
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.
Varadarajan K, Cruz Pico CX, Evans KW, Raso MG, Rizvi YQ, Zheng X, Chachad D, DiPeri TP, Wang B, Scott SM, Zhao M, Akcakanat A, Wengner AM, Yap TA, Meric-Bernstam F. Varadarajan K, et al. Among authors: evans kw. Mol Cancer Ther. 2025 Sep 2;24(9):1402-1414. doi: 10.1158/1535-7163.MCT-24-0884. Mol Cancer Ther. 2025. PMID: 40300249 Free PMC article.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein L, Welm A, Dean DA 2nd, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm B, Govinden R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona L, Herylyn M, Davies MA, Shapiro GI, Fields R, Trevino JG, Harrell JC; NCI PDXNet Consortium; Doroshow JH, Chuang JH, Moscow JA. Meric-Bernstam F, et al. Among authors: evans kw. Mol Cancer Ther. 2024 Jul 2;23(7):924-938. doi: 10.1158/1535-7163.MCT-23-0471. Mol Cancer Ther. 2024. PMID: 38641411 Free PMC article.
Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan.
Zhao M, Wang B, Evans KW, Scott S, Yuca E, Raso G, Rizvi YQ, Zheng X, Li D, Li J, Liang H, Akcakanat A, Brockman M, Damodaran S, Meric-Bernstam F. Zhao M, et al. Among authors: evans kw. J Natl Cancer Inst. 2026 Aug 8:djag266. doi: 10.1093/jnci/djag266. Online ahead of print. J Natl Cancer Inst. 2026. PMID: 42569934 Free article.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. DiPeri TP, et al. Among authors: evans kw. J Hepatol. 2024 Feb;80(2):322-334. doi: 10.1016/j.jhep.2023.10.041. Epub 2023 Nov 14. J Hepatol. 2024. PMID: 37972659 Free PMC article.
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Evans KW, et al. Cancer Res. 2021 Nov 1;81(21):5572-5581. doi: 10.1158/0008-5472.CAN-20-3242. Epub 2021 Sep 13. Cancer Res. 2021. PMID: 34518211 Free PMC article.
41 results